Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. company information, Employees & Contact Information

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 30 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States. We market Qelbree® (viloxazine extended-release) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children ages 6 to 17. Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Company Details

Employees
741
Founded
-
Address
9715 Key West Ave, Rockville,maryland 20850,united States
Phone
3014241385
Email
in****@****nus.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Rockville, Maryland
Looking for a particular Supernus Pharmaceuticals, Inc. employee's phone or email?

Supernus Pharmaceuticals, Inc. Questions

News

Supernus Pharmaceuticals to Announce Third Quarter 2025 - GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 GlobeNewswire

Supernus Pharmaceuticals, Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 - Quiver Quantitative

Supernus Pharmaceuticals, Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 Quiver Quantitative

Supernus Pharmaceuticals (NASDAQ: SUPN) to report third-quarter 2025 results on Nov. 4 - Stock Titan

Supernus Pharmaceuticals (NASDAQ: SUPN) to report third-quarter 2025 results on Nov. 4 Stock Titan

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Supernus Pharmaceuticals To Acquire Sage Therapeutics citybiz

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Yahoo Finance

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer Yahoo Finance

Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 | SUPN Stock News - Quiver Quantitative

Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 | SUPN Stock News Quiver Quantitative

CNS Drug Developer Supernus Pharmaceuticals Announces Triple Conference Schedule for September 2025 - Stock Titan

CNS Drug Developer Supernus Pharmaceuticals Announces Triple Conference Schedule for September 2025 Stock Titan

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 - Yahoo Finance

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 Yahoo Finance

Supernus Announces Second Quarter 2025 Financial Results - GlobeNewswire

Supernus Announces Second Quarter 2025 Financial Results GlobeNewswire

Supernus Pharmaceuticals, Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025 - Quiver Quantitative

Supernus Pharmaceuticals, Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025 Quiver Quantitative

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics GlobeNewswire

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio GlobeNewswire

Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan

Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears Stock Titan

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD - GlobeNewswire

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD GlobeNewswire

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease - GlobeNewswire

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease GlobeNewswire

What Questions Should Investors Ask Supernus CEO at Upcoming TD Cowen Conference? - Stock Titan

What Questions Should Investors Ask Supernus CEO at Upcoming TD Cowen Conference? Stock Titan

Supernus Announces Label Update for Non-Stimulant ADHD - GlobeNewswire

Supernus Announces Label Update for Non-Stimulant ADHD GlobeNewswire

Supernus Pharmaceuticals' CEO to Speak at 36th Annual Piper Sandler Healthcare Conference - Quiver Quantitative

Supernus Pharmaceuticals' CEO to Speak at 36th Annual Piper Sandler Healthcare Conference Quiver Quantitative

Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - Quiver Quantitative

Supernus Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 Quiver Quantitative

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree - Yahoo Finance

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree Yahoo Finance

Supernus to Defend Qelbree Patents Until 2035 Against Multiple Generic Challengers - Stock Titan

Supernus to Defend Qelbree Patents Until 2035 Against Multiple Generic Challengers Stock Titan

Busy Philipps Empowers Women with ADHD to Go from Feeling - GlobeNewswire

Busy Philipps Empowers Women with ADHD to Go from Feeling GlobeNewswire

Supernus: New Approval Holds Promise Of Increased Growth (SUPN) - Seeking Alpha

Supernus: New Approval Holds Promise Of Increased Growth (SUPN) Seeking Alpha

Bethany L. Sensenig Joins Supernus’ Board of Directors - citybiz

Bethany L. Sensenig Joins Supernus’ Board of Directors citybiz

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America - PR Newswire

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America PR Newswire

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals - Yahoo Finance

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals Yahoo Finance

Supernus Announces FDA Approval of Qelbree® - MultiVu

Supernus Announces FDA Approval of Qelbree® MultiVu

Supernus Announces First Quarter 2021 Financial Results - GlobeNewswire

Supernus Announces First Quarter 2021 Financial Results GlobeNewswire

Supernus to Acquire CNS Portfolio from US WorldMeds - GlobeNewswire

Supernus to Acquire CNS Portfolio from US WorldMeds GlobeNewswire

Top Supernus Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant